Rajkummar Rao is undoubtedly one of the busiest actors in Bollywood. He is currently gearing up for the direct-to-digital release of his two films Ludo (Netflix) and Chhalaang (Amazon Prime Video) and has four other films lined-up.
One of the upcoming films of Rao is the remake of Chupke Chupke. The original film starred Dharmendra, Sharmila Tagore, Amitabh Bachchan, and Jaya Bachchan. The actor will be stepping into the shoes of Dharmendra for the remake and according to a report in Mumbai Mirror, the shooting of the film will kickstart in March 2021.
A source told the tabloid, “The script is undergoing some rewrites as the makers are determined to do justice to the original. They are also in talks with several actors for the role of Sukumar, professor of English masquerading as Parimal, and trying to teach botany, enacted by Amitabh Bachchan in the original. The cast should be locked by December.”
Meanwhile, Rao is all set to start shooting for his next untitled film with Kriti Sanon. The movie goes on the floors this week in Chandigarh. The source stated, “He flies to Chandigarh today with the entire team. It’s a marathon schedule, to be shot at real locations, and will continue till the year-end.”
Well, apart from Chupke Chupke remake and the untitled film with Kriti, Rao has movies like Badhaai Do and the remake of Telugu film Hit in his kitty. While Badhaai Do starts rolling in January next year, Hit remake might go on the floors by end of April or in May.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.